Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$11.52 USD
+0.31 (2.77%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TBPH 11.52 +0.31(2.77%)
Will TBPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Other News for TBPH
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 | TBPH ...
Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News
Theravance Biopharma (TBPH) Target Price Raised to $25 By BTIG | TBPH Stock News
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News
Theravance Biopharma price target raised to $25 from $24 at BTIG